Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

Chiara Rosa Mancinelli,Cristina Scarpazza,Cinzia Cordioli,Nicola De Rossi,Sarah Rasia,Maria Vittoria Turrini,Ruggero Capra

Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.

2020

Chiara Rosa Mancinelli
Cristina Scarpazza
Cinzia Cordioli
Nicola De Rossi
Sarah Rasia
Maria Vittoria Turrini
Ruggero Capra

Discontinuation of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) at risk of progressive multifocal leukoencephalopathy (PML) is associated with disease reactivation. Fo...

Keywords:

in patient
Discontinuation
Progressive multifocal leukoencephalopathy
Extended interval dosing
Oncology
previously treated
Internal medicine
Ocrelizumab
Multiple sclerosis
Medicine
Natalizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations